Cerecor Inc. (NASDAQ:CERC) Director Armistice Capital, Llc bought 10,000 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was bought at an average cost of $1.20 per share, for a total transaction of $12,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Armistice Capital, Llc also recently made the following trade(s):

  • On Wednesday, November 22nd, Armistice Capital, Llc bought 35,200 shares of Cerecor stock. The stock was bought at an average cost of $1.20 per share, for a total transaction of $42,240.00.
  • On Wednesday, September 20th, Armistice Capital, Llc bought 15,250 shares of Cerecor stock. The stock was bought at an average cost of $0.76 per share, for a total transaction of $11,590.00.
  • On Tuesday, September 19th, Armistice Capital, Llc bought 30,119 shares of Cerecor stock. The stock was bought at an average cost of $0.74 per share, for a total transaction of $22,288.06.
  • On Monday, September 18th, Armistice Capital, Llc bought 6,000 shares of Cerecor stock. The stock was bought at an average cost of $0.78 per share, for a total transaction of $4,680.00.
  • On Friday, September 8th, Armistice Capital, Llc bought 2,060 shares of Cerecor stock. The stock was bought at an average cost of $0.75 per share, for a total transaction of $1,545.00.
  • On Wednesday, September 6th, Armistice Capital, Llc bought 2,239 shares of Cerecor stock. The stock was bought at an average cost of $0.74 per share, for a total transaction of $1,656.86.
  • On Friday, September 1st, Armistice Capital, Llc bought 13,867 shares of Cerecor stock. The stock was bought at an average cost of $0.73 per share, for a total transaction of $10,122.91.
  • On Thursday, August 31st, Armistice Capital, Llc bought 25,100 shares of Cerecor stock. The stock was bought at an average cost of $0.77 per share, for a total transaction of $19,327.00.
  • On Wednesday, August 30th, Armistice Capital, Llc bought 512 shares of Cerecor stock. The stock was bought at an average cost of $0.74 per share, for a total transaction of $378.88.

Cerecor Inc. (CERC) remained flat at $$1.18 during trading hours on Friday. 39,086 shares of the stock traded hands, compared to its average volume of 189,537. The firm has a market cap of $30.74, a price-to-earnings ratio of 118.00 and a beta of 2.13. Cerecor Inc. has a one year low of $0.34 and a one year high of $5.57.

A number of research firms recently issued reports on CERC. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th.

ILLEGAL ACTIVITY NOTICE: “Cerecor Inc. (CERC) Director Armistice Capital, Llc Purchases 10,000 Shares” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/cerecor-inc-cerc-director-armistice-capital-llc-purchases-10000-shares/1726273.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.